scholarly journals Secondary Leukemia in a non-Hodgkin's Lymphoma Patient Presenting as Myeloid Sarcoma of the Breast

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Vincenzo Pitini ◽  
Carmela Arrigo ◽  
Maria Grazia Sauta ◽  
Giuseppe Altavilla
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Myeloid Sarcoma ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
Secondary Leukemia ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Immature Myeloid Cells ◽  
Classification Of Tumors ◽  
Health Organization

As defined by the World Health Organization classification of tumors of hematopoietic and lymphoid tissue, myeloid sarcoma (MS) is a tumor mass of myeloblasts or immature myeloid cells that can arise before, concurrent with, or following acute myeloid leukaemia. We describe a case of secondary leukemia presenting itself as MS of the breast in a patient previously treated for a non-Hodgkin's Lymphoma.

California's Glyphosate Judgement – Emotion, Bad Science and Greed Win the Day

2018 ◽  
Vol 29 (5) ◽  
pp. 204-205
Author(s):  
Alex Berezow
Keyword(s):  
World Health Organization ◽  
Hodgkin’S Lymphoma ◽  
Hot Water ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
International Agency ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The World ◽  
Health Organization

Jurors in California have awarded $289 million to a man who claimed that his cancer was due to Monsanto's herbicide glyphosate, even though that is biologically impossible. Even the judge acknowledged that there was no evidence of harm. Yet, trial lawyers manipulated a jury's emotions and the public's misunderstanding of science to score another jackpot verdict. The plaintiff, Dewayne Johnson, claims that glyphosate gave him non-Hodgkin's lymphoma, a cancer that occurs when the immune system goes awry. There are three major problems with this claim. First, as stated above, glyphosate does not cause cancer because it does not harm humans. It is an herbicide, so it is only toxic to plants. There is no known biological mechanism by which glyphosate could cause cancer, therefore its carcinogenicity is not even theoretically possible. That is why there is not a single reputable public health agency that believes glyphosate causes cancer. The US Environmental Protection Agency, the World Health Organization, and the European Food Safety Authority all reject claims of any link. The only organization of note that rejects this scientific consensus is a group within the World Health Organization called the International Agency for Research on Cancer (IARC). Contrary to all evidence, the group insists that glyphosate causes cancer – along with bacon and hot water. The truth is that IARC is a fringe outlier, staunchly ideological rather than scientific, and rife with financial conflicts of interest. Christopher Portier, a special adviser to the IARC working group that examined glyphosate, was also working for the activist organization the Environmental Defense Fund and received $160,000 from trial lawyers who stood to profit handsomely if IARC declared glyphosate a carcinogen because they could file suits in lawsuit-happy California. IARC's credibility has been so thoroughly shattered that Congress recently pulled its funding. Secondly, although the root cause of non-Hodgkin's lymphoma is unknown, that does not mean its etiology is completely open to speculation. Lymphomas originate from white blood cells, so scientists believe that autoimmune disease or chronic infections play a role. Just because the plaintiff's attorneys can fool a jury into believing that glyphosate causes non-Hodgkin's lymphoma does not mean there is any scientific evidence – and there is not. Thirdly, glyphosate has been off-patent for 18 years, and about 40% of the world's glyphosate is made in China. So, why pick on Monsanto when several different companies could have supplied the glyphosate the plaintiff used?

scholarly journals Primary B-Cell Lymphoma of Caecum Presenting as an Ulcerative Lesion in a Young Male

2020 ◽  
Vol 11 (02) ◽  
pp. 159-162
Author(s):  
Arvind Bamanikar ◽  
Swapnil Patil ◽  
Shivam Sharma
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
Young Male ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Health Organization

AbstractExtra nodal site of non–Hodgkin’s lymphoma is mostly in the gastrointestinal tract. Large intestine is rarely affected compared with stomach or small bowel. The colon is affected in 0.4% of cases approximately. High index of suspicion is required to establish the diagnosis, since there may be no specific signs. Here we report a case of a 28-year-old male, who presented with diarrhea , abdominal pain and weight loss of 2-month duration and diagnosed as non-Hodgkin’s lymphoma (NHL) of the cecum as B-cell lymphoma, unclassified (BCLU) according to World Health Organization (WHO) guidelines.

Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.

1996 ◽  
Vol 14 (3) ◽  
pp. 945-954 ◽  
Author(s):  
E M Bessell ◽  
F Graus ◽  
J A Punt ◽  
J L Firth ◽  
D T Hope ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Whole Brain Radiotherapy ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
Poor Performance Status ◽  
Significant Treatment ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE To assess whether chemotherapy that includes drugs that cross the blood-brain barrier improves survival in primary CNS non-Hodgkin's lymphoma (PCNSL) when combined with radiotherapy. PATIENTS AND METHODS Thirty-four patients, with no evidence of human immunodeficiency virus type 1 (HIV-1) infection, were treated with the related chemotherapy regimens of carmustine (BCNU), vincristine, cytarabine, and methotrexate (BVAM; 12 patients), cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/BVAM (17 patients) and intensified CHOD/BVAM (five patients) between 1986 and 1994. The median age was 60 years (range, 16 to 73) and 47% had a performance status of 3 or 4 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO]). Ten patients were treated with BVAM chemotherapy between 1986 and 1989, and subsequently 17 patients were treated with CHOD/BVAM (cytarabine 3 g/m2). Twenty of these 27 patients received whole-brain radiotherapy (craniospinal in four). RESULTS The complete response (CR) rate at the completion of chemotherapy was 63% for BVAM and 67% for CHOD/BVAM; more neutropenia occurred with CHOD/BVAM. The 5-year actuarial probability of survival of all 34 patients was 33% (95% confidence interval [CI], 14% to 52%), with so far only one recurrence after 2 years. Using multivariate analysis, age (P = .0005) and number of tumors at diagnosis (P = .0358) were prognostic factors. All five patients aged > or = 70 years died during or shortly after chemotherapy. Performance status was not an independent variable. CONCLUSION The BVAM or CHOD/BVAM regimens can be delivered despite neutropenia without significant treatment delay or dose reduction in patients less than 70 years of age. Further intensification of this type of chemotherapy is probably not possible with patients of this age, many of whom have a poor performance status.

scholarly journals Diagnostic and Prognostic Importance of Chromosomal Aberrations Identified in 61 Dogs with Lymphosarcoma

1994 ◽  
Vol 31 (5) ◽  
pp. 528-540 ◽  
Author(s):  
K. A. Hahn ◽  
R. C. Richardson ◽  
E. A. Hahn ◽  
C. L. Chrisman
Keyword(s):  
Survival Time ◽  
Chromosomal Aberrations ◽  
Hodgkin’S Lymphoma ◽  
Treatment Protocol ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
First Remission ◽  
Prognostic Importance

To determine the diagnostic and/or prognostic importance of chromosomal aberrations identified in dogs with malignant (non-Hodgkin's) lymphoma, clinical stages for 61 dogs with lymphosarcoma were determined, the lymph node(s) were histopathologically graded, and the malignant tissue lymphocytes were karyotyped. The results from life table survival curve analysis demonstrated that first remission length and survival time were significantly longer in 15 of 61 (25%) dogs that had a trisomy of chromosome 13 as the primary chromosomal aberration than in those dogs (46/61, 75%) with other primary chromosomal aberrations ( P < 0.05). Sex, age, weight, histopathologic subtype and grade, World Health Organization (WHO) clinical stage, WHO and modified Karnofsky performance status, chromosomal modal number, and treatment protocol were of no prognostic importance in predicting first remission length or survival time ( P > 0.05). Multivariate analysis did not identify a significant correlation between the prognostic groups or within the various prognostic subsets ( P > 0.05). The pathogenesis of canine and human non-Hodgkin's lymphoma, as observed cytogenetically, differs.

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

1996 ◽  
Vol 14 (1) ◽  
pp. 227-232 ◽  
Author(s):  
M A Fridrik ◽  
H Hausmaninger ◽  
W Linkesch ◽  
M Stöger ◽  
H Sill ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Multicenter Trial ◽  
Observation Time ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
High Grade ◽  
Community Hospitals ◽  
Who Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter setting of university and community hospitals. PATIENTS AND METHODS We tested a hybrid protocol of two non-cross-resistant regimens, cyclophosphamide, epirubicin, vincristine, and prednisolone (CEOP) and ifosfamide, etoposide (VP-16), methotrexate, and dexamethasone (IMVP-Dexa) given every fourth week, three to six times according to response, in patients with untreated intermediate- and high-grade non-Hodgkin's lymphoma. Ten Austrian centers entered 81 patients onto this multicenter trial. Eleven patients were excluded. The median age was 55 years. Twenty-six of 70 patients had stage III or IV disease. The distribution among international risk categories low, intermediate-low, intermediate-high, and high was 20%, 34%, 23%, and 23%, respectively. RESULTS Of 70 eligible patients, 56 (80%) had a complete remission and seven (10%) a partial remission. After a median observation time of 36 months, the estimated time to relapse and overall survival rates are 67% and 72%, respectively. Age and Karnofsky index were the only independent risk factors for survival. Toxicity was primarily hematologic, with a median granulocyte nadir of 0.56 x 10(9)/L. Sixty-seven percent of patients had infections; 25.7% were severe World Health Organization (WHO) grade III or IV. There were three treatment-related deaths. CONCLUSION CEOP-IMVP-Dexa chemotherapy is safe and feasible on a groupwide basis even when used in community hospitals. Neutropenic infections are the major complications. A 72% 3-year survival rate in patients with intermediate- and high-grade non-Hodgkin's lymphoma warrants further studies. These data are the basis for a randomized trial to compare cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with CEOP/IMVP-Dexa.

scholarly journals Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

2019 ◽  
Vol 12 (4) ◽  
pp. 141 ◽  
Author(s):  
Sachpekidis ◽  
Jackson ◽  
Soldatos
Keyword(s):  
Adverse Event ◽  
Monoclonal Antibodies ◽  
Hodgkin’S Lymphoma ◽  
Single Agent ◽  
Adverse Event Reporting System ◽  
Hodgkin's Lymphoma ◽  
World Health ◽  
Antibody Treatment ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-agent therapies. In this context, radioimmunotherapy, the administration of radionuclides conjugated to monoclonal antibodies, is aimed to augment the single-agent efficacy of immunotherapy in order to deliver targeted radiation to tumors, particularly CD20+ B-cell lymphomas. Based on evidence from several trials in NHL, the radiolabeled antibodies 90Y-ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals) and 131I-tositumomab (Bexxar, GlaxoSmithKline) received FDA approval in 2002 and 2003, respectively. However, none of the two radioimmunotherapeutic agents has been broadly applied in clinical practice. The main reason for the under-utilization of radioimmunotherapy includes economic and logistic considerations. However, concerns about potential side effects have also been raised. Driven by these developments, we performed retrospective analysis of adverse events reporting Zevalin or Bexxar, extracted from the FDA’s Adverse Event Reporting System (FAERS) and the World Health Organization’s VigiBase repository. Our results indicate that the two radioimmunotherapeutic agents have both related and distinct side effect profiles and confirm their known toxicological considerations. Our work also suggests that computational analysis of real-world post-marketing data can provide informative clinical insights. While more prospective studies are necessary to fully characterize the efficacy and safety of radioimmunotherapy, we expect that it has not yet reached its full therapeutic potential in modern hematological oncology.

Sign in / Sign up

Export Citation Format

Share Document